Radius Health (NASDAQ:RDUS) has been given a $58.00 target price by Cantor Fitzgerald in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 102.37% from the company’s previous close.
Several other equities research analysts have also recently weighed in on RDUS. Maxim Group reiterated a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Zacks Investment Research cut shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Goldman Sachs Group restated a “neutral” rating and set a $45.00 price target on shares of Radius Health in a research note on Friday, October 6th. Jefferies Group cut their price target on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday, November 3rd. Finally, ValuEngine upgraded shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Three analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $48.00.
Radius Health (NASDAQ:RDUS) traded down $0.96 during midday trading on Friday, hitting $28.66. 1,100,600 shares of the company traded hands, compared to its average volume of 976,504. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. Radius Health has a twelve month low of $24.66 and a twelve month high of $49.16.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same period in the previous year, the firm posted ($1.07) EPS. sell-side analysts anticipate that Radius Health will post -5.57 earnings per share for the current year.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 50,000 shares of the business’s stock in a transaction on Wednesday, October 25th. The stock was purchased at an average price of $32.85 per share, for a total transaction of $1,642,500.00. Following the completion of the purchase, the insider now directly owns 5,548,799 shares in the company, valued at $182,278,047.15. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jesper Hoiland bought 6,800 shares of the business’s stock in a transaction dated Tuesday, November 7th. The stock was purchased at an average price of $29.04 per share, with a total value of $197,472.00. Following the purchase, the insider now directly owns 12,900 shares of the company’s stock, valued at approximately $374,616. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 158,578 shares of company stock valued at $4,659,916. Corporate insiders own 15.00% of the company’s stock.
Large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new position in shares of Radius Health in the third quarter valued at approximately $110,000. Sei Investments Co. raised its stake in shares of Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 690 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after acquiring an additional 541 shares during the last quarter. Advisor Group Inc. raised its stake in shares of Radius Health by 267.2% in the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 2,888 shares during the last quarter. Finally, Blair William & Co. IL bought a new position in shares of Radius Health in the second quarter valued at approximately $205,000.
ILLEGAL ACTIVITY WARNING: “Radius Health (RDUS) Given a $58.00 Price Target by Cantor Fitzgerald Analysts” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://ledgergazette.com/2017/12/15/radius-health-rdus-given-a-58-00-price-target-by-cantor-fitzgerald-analysts-2.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.